Replimune Q3 net loss $66.3M; FDA accepts RP1 BLA with priority review, PDUFA July 22

Replimune Group, Inc.

2025-Q3 EPS reported -$2.25 vs consensus -$0.80 ▼ miss (-180.8%)

FDA accepted BLA for RP1+nivolumab in advanced melanoma with Priority Review; PDUFA date July 22, 2025.
Net loss $66.3M for fiscal Q3 2025, up from $51.1M in Q3 2024; R&D expense $48.0M.
Cash & investments $536.5M as of Dec 31, 2024, expected to fund operations into Q4 2026.
Public offering raised ~$156M net to support RPx development and potential commercial launch.
First patients enrolled in RP2 registration-directed trial for uveal melanoma and Phase 2 HCC trial.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.